Dr. Zakharia on phase 2 study of durvalumab and RT in urothelial cancer

Video

Yousef Zakharia, MD, discusses the design and results of a phase 2 trial that explored concurrent treatment with radiation and the PD-L1 inhibitor durvalumab (Imfinzi) followed by adjuvant durvalumab in patients with urothelial cancer. Zakharia is clinical associate professor of internal medicine at the University of Iowa, Holden Comprehensive Cancer Center.

Related Videos
Dr. Kyle A. Richards in an interview with Urology Times
3d rendered illustration - bladder cancer | Image Credit: © SciePro - stock.adobe.com
Randie White, MD, answers a question during a Zoom video interview
Hospital hallway | Image Credit: © Paolese - stock.adobe.com
James Ferguson III, MD, PhD, answers a question during a Zoom video interview
3d rendered illustration of bladder cancer | Image Credit: © SciePro - stock.adobe.com
Related Content
© 2023 MJH Life Sciences

All rights reserved.